Doctor and female patient talking

Variation in the types of providers participating in breast cancer follow-up care

Variation in the types of providers participating in breast cancer follow-up care

Dr. Heather Neuman et al. aimed to describe the types of providers participating in early follow-up care of older breast cancer survivors. Using the SEER-Medicare database, investigators found 80% of follow-up care was with a medical oncologist, 46% with a surgeon, and 39% with a radiation oncologist after radiation treatment. Patients with larger tumor size, positive axillary nodes, estrogen receptor-positive status, and chemotherapy treatment were more llikely to have medical oncology follow-up.

Read the article

Colorectal cancer

PCP perceptions of colorectal cancer screening barriers

PCP perceptions of colorectal cancer screening barriers

Dr. Jennifer Weiss and team examined groups of PCPs based on their perceptions of screening barriers and the relationship to their patients' CRC screening rates to inform approaches for conducting barrier assessments prior to designing and implementing QI interventions. They found that high-performing PCPs can more effectively identify CRC screening barriers. Targeting high-performers when conducting a barriers assessment would assist in designing QI interventions for CRC screening.

Read the article

Using a microscope

The role of intraoperative assessment in the surgical management of ductal carcinoma in situ

The role of intraoperative assessment in the surgical management of ductal carcinoma in situ

This study by Dr. Marquita Decker et al. examined the relationship between intraoperative pathologic assessment and subsequent operations in patients with a diagnosis of ductal carcinoma in situ (DCIS). Using SEER-Medicare data, investigators found that the use of intraoperative frozen section or touch preparation during partial mastectomy did not result in a reduction in subsequent breast operations in women with DCIS.

Read the article

Woman reviewing results with doctor

Patient demographic and tumor characteristics influencing oncologist follow-up frequency in older breast cancer survivors

Patient demographic and tumor characteristics influencing oncologist follow-up frequency in older breast cancer survivors

Dr. Heather Neuman et al. studied current patterns of oncologist breast cancer follow-up to determine the association between patient and tumor characteristics and follow-up frequency. Using SEER-Medicare data, the authors found young age, positive nodes, estrogen/progesterone receptor positivity, and increasing treatment intensity were most strongly associated with more frequent follow-up. Number and types of oncologists also were associated with different follow-up frequencies. 

Read the article

Doctor writing order

Predictors of colorectal cancer screening variation among primary care providers and clinics

Predictors of colorectal cancer screening variation among primary care providers and clinics

Dr. Jennifer Weiss et al. used EMR data and a survey of primary care providers (PCPs) to evaluate patient, provider, and clinic factors that predict variation in colorectal cancer (CRC) screening among PCPs and clinics. They found that screening rates varied from 51-80% among clinics from 51-82% among PCPs, and identified significant predictors of completing CRC screening at the patient, provider, and clinic level, indicating that quality improvement interventions addressing CRC screening should be addressed at multiple levels of the health care system.

Read the article

Patient being led into CT scanner

5 year colorectal cancer outcomes in a large negative CT colonography screening cohort

5 year colorectal cancer outcomes in a large negative CT colonography screening cohort

In this study co-authored by Dr. Jennifer Weiss, the authors examined the 5-year incidence of clinically presenting colorectal cancers following a negative CT colonography (CTC) screening. The study found that clinically presenting cancers are rare in the 5 years following a negative CTC screening, a 6mm polyp size threshold is safe, and a 5-year CTC screening interval is appropriate. The results indicate that the current strategies for CTC screening for colorectal cancer are appropriate.

Read the article

Colon cancer

Mortality by stage for right vs. left-sided colon cancer

Mortality by stage for right vs. left-sided colon cancer

In this article by Dr. Jennifer Weiss et al., the authors used SEER-Medicare data to predict all-cause 5-year mortality by colon cancer stage and location. There was no significant difference in 5-year mortality between right- and left-sided cancers for all stages combined or for stage I cancers. Right-sided cancers had a lower 5-year mortality in stage II and higher mortality in stage III. 

Read the article

IV bag

Amongst eligible patients, age and comorbidity do not predict for dose limiting toxicity from phase I chemotherapy

Amongst eligible patients, age and comorbidity do not predict for dose limiting toxicity from phase I chemotherapy

Dr. Noelle LoConte et al. sought to identify clinical and non-clinical factors which were associated with the development of dose-limiting toxicity in phase I studies. Over 200 charts were reviewed from 24 cytotoxic chemotherapy studies and Cumulative Illness Rating Score-Geriatrics (CIRS-G) score was not associated with dose-limiting toxicity. Several social and clinical factors may predict for development of dose-limiting toxicity.

Read the article

Pages